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Abstract
Background: Migraine is a highly prevalent disorder. The disability provoked by its attacks results
in suffering as well as considerable economic and social losses. The objective of migraine acute
treatment is to restore the patient to normal function as quickly and consistently as possible. There
are numerous drugs available for this purpose and despite recent advances in the understanding of
the mechanisms and different biological systems involved in migraine attacks, with the development
of specific 5-HT agonists known as triptans, current options for acute migraine still stand below the
ideal.
Discussion:  Monotherapeutic approaches are the rule but up to one third of all patients
discontinue their medications due to lack of efficacy, headache recurrence, cost and/or side effects.
In addition, a rationale has been suggested for the development of polytherapeutic approaches,
simultaneously aiming at some of the biological systems involved. This paper reviews the
fundamentals for this changing approach as well as the evidence of its better efficacy.
Conclusion: As a conclusion, most of the patients with a past history of not responding (no pain-
free at 2 hours and/or no sustained pain-free at 24 hours) in at least 5 previous attacks should
undergo a combination therapy suiting to their individual profile, which must include analgesics or
non-steroidal anti-inflammatory agents plus a triptan or a gastro kinetic drug. The three-drug
regimen may also be considered. In addition, changing the right moment to take it and the choice
for formulations other than oral has also to be determined individually and clearly posted to the
patient.
Background
Migraine is a highly prevalent disorder which manifests
clinically as moderate to severe or severe headache attacks
with frequent frontotemporal unilateral location and
associated symptoms [1-3]. The pain is pulsating and/or
pressure-type, usually associated with nausea, photopho-
bia, phonophobia and osmophobia. Its attacks promote
disability and generally worsen with physical activities.
The duration may last from 4 to 72 hours when not
treated or treated ineffectively [3]. The headache fre-
quency is variable and some patients may present it on a
weekly basis while others will have it less than once a
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month [4]. The disability of migraine results in consider-
able economic and social losses [5].
Migraine attacks may present with four distinct phases:
(1) prodromic phase with premonitory symptoms, (2)
aura phase with transient neurological symptoms and
signs, (3) headache phase with associated features and (4)
recovery or postdromic phase frequently associated with
resting and sleeping. Only the headache phase can be
treated and despite the advances in understanding
migraine, considerable uncertainty surrounding an effec-
tive and definitive way of treating the attacks remains
[6,7].
The objective of acute migraine therapy is to restore the
patient to normal function by rapidly and consistently
alleviating the head pain and the associated symptoms of
nausea, vomiting and sensory phobias without side effects
and recurrence of the attack within 24 hours [8]. Several
drug options and different formulations are available to
treat migraine acutely. The choice of a specific medication
type depends on individual characteristics such as head-
ache intensity, speed of onset of action, presence of asso-
ciated symptoms, the degree of incapacitation, and the
patient's response [9].
There are specific and non-specific treatments for
migraine attacks. Non-specific treatments, such as aspirin,
acetaminophen, non-steroidal anti-inflammatory drugs
(NSAIDs), opioids, and combination analgesics, are used
to treat migraine and a wide range of pain disorders [10].
Specific treatments, including ergotamine, dihydroergot-
amine and the triptans are effective for treating the attacks
of primary headaches with neurovascular mechanisms,
such as migraine and cluster headache, but not for treating
other types of headaches [11].
Discussion
Reasons for changing the approach
Clinicians know that some patients do respond well to
simple analgesics in a monotherapeutic approach but
despite the advent of newer, highly effective migraine
acute therapies, most of the patients still want rapid onset
of complete pain relief [12], which cannot be provided by
most of the current individual options for migraine treat-
ment [13]. Although the triptans represented a tremen-
dous positive impact on patient care and clinical practice,
they are still far away from the optimum. Monotherapy
using these selective 5-HT1B/1D agonists, especially
orally, does not result in rapid, consistent, and complete
relief of migraine in all patients [14]. The response rates in
numerous controlled trials vary considerably. The aura
phase of patients with migraine with aura can't be effec-
tively treated, side effects may occur in up to 89% of the
patients and up to 31% of those taking sumatriptan dis-
continue its use due to lack of efficacy, headache recur-
rence, cost and/or side effects [15-18]. In addition, most
of these studies were performed using the endpoint head-
ache relief (from moderate or severe to mild or none)
rather than the current standard of headache free at 2
hours [19]. Moreover, due to variable placebo response
rates, one must have to pursue parameters of therapeutic
gain instead of absolute response [20].
Subcutaneous sumatritpan for instance, still considered
the most efficacious drug for a migraine attack, promotes
headache relief with a therapeutic gain of 51–52% [20].
The other triptans and triptan formulations range from 10
to 47% with regard to therapeutic gain. On the other
hand, ergotamine derivatives have been used for over 40
years but little evidence exists that it is significantly more
effective than placebo [21]. Although largely used in some
countries, its pharmacokinetic is totally unpredictable,
with oral and rectal bioavailability of less than 5%, which
do not provide consistency through all attacks within the
same patient [22,23]. Other options for migraine attacks
include analgesics alone or combined with caffeine and/
or metoclopramide and NSAID. These compounds vary
largely in characteristics but in regard to efficacy may dem-
onstrate therapeutic gains similar to 100 mg sumatriptan
(around 29–30%)[24]. Recurrence, the returning of the
headache within 24 hours after it has become mild or
absent, is also a problem with triptans and with other
acute migraine treatments. The use of sumatriptan, for
example, may bring up recurrence after 6–7 h with the
nasal spray, after 17 h with the tablets and after 10 h with
the subcutaneous formulation [25]. The recurrence may
require re-dosing, which can cause excessive use and more
dissatisfaction with available treatments [26].
In addition, recent evidence has demonstrated that once
peripheral and central sensitization occurs and allodynia
cutanea develops, the triptans and other acute therapies
will not work efficiently in order to provide consistent
relief [27]. Moreover, migraine seems to involve different
pathophysiological mechanisms named as "low" serot-
onin, neurogenic inflammation and dopaminergic hyper-
sensitivity which implies that addressing one of the
involved biological systems will always stand bellow the
ideal [14]. The consistent demonstration of changes in 5-
HT levels during migraine has ever been found in all
migraineurs but alterations in 5-HT levels in metabolism
have been reported by many investigators [14,28]. The
inflammation in migraine is crucial. Transient distur-
bances in cortical sensory functions release potassium and
hydrogen ions in the vicinity of sensory fibers that inner-
vate the dura, which could activate C-fiber meningeal
nociceptors and secretion of calcitonin-gene-related-pep-
tide, therefore initiating neurogenic inflammationBMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/4
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[29,30] with the introduction of histamine, serotonin,
bradykinin, and prostaglandins into this environment.
Mechanical hypersensitivity develops in receptors located
in the dura mediating the throbbing of the headache and
it's worsening during coughing, bending, or other physi-
cal activities that increase intracranial pressure [31]. In
addition, the inflammation activates and sensitizes dorsal
horn neurons leading to cutaneous allodynia in the ipsi-
lateral periorbital skin followed by the expanding of
receptive fields to the contralateral periorbital areas as
well [32]. Finally, dopaminergic hypersensitivity has been
documented in migraine by data demonstrating that
migraineurs are more sensitive to the effects of dopamin-
ergic agonists than nonmigraineurs. It is corroborated by
the observation that many components of a migraine
attack such as yawning, nausea, hypotension, cerebral
blood flow changes and headache are induced by doses of
dopamine agonists that have no effect in nonmigraineurs
[14,33-36]. All of these facts point to a path of combining
drugs aiming at different mechanisms and systems
involved in migraine, at least in certain subsets of patients
not responsive to traditional approaches, with regard to
pain-free and sustained pain-free endpoints. But, does the
simultaneous action on various pathophysiological
mechanisms really improve efficacy and outcome?
Evidence of better efficacy
Monotherapeutic approaches to each of the biological sys-
tems involved in migraine result in definite, but often sub-
optimal, relief of a migraine attack. Therefore, it follows
logically that polytherapy targeting more than one of
these systems should be more efficacious than addressing
only a single mechanism involved in migraine pathophys-
iology [14]. In addition, drugs rapid achieving onset of
action could be able to function before the central sensiti-
zation and the development of cutaneous allodynia, pro-
viding better consistency across multiple attacks. Even
prior to the introduction of 5-HT agonists, it was demon-
strated that combining therapies result in better outcome.
Lance recommended metoclopramide to be given before
the administration of an ergot derivative in order to allow
a faster gastric absorption, which is impaired during a
migraine attack [37]. Wilkinson reported that 61% of her
patients had total or significant relief of migraine follow-
ing a regimen that included a dopamine antagonist, a sim-
ple analgesic, and an attempt to sleep. In the remaining
patients, an ergot preparation was added and resulted in a
total efficacy rate of 91% [38]. The combination of dihy-
droergotamine (DHE) plus prochlorperazine adminis-
tered intravenously revealed to be a highly effective
emergency room scheme as proposed by Callaham and
Raskin [39]. We have been demonstrating that the combi-
nation of sumatriptan plus a NSAID such as tolfenamic
acid or naproxen sodium reduces recurrence in clinical
practice. In our first study, 240 moderate or severe attacks
were treated with 100 mg sumatriptan and 200 mg of
tolfenamic acid resulting in a decreasing recurrence rate
from 62,5% to 23,8%. However, this was an open retro-
spective study, therefore, limiting further conclusions
[40].
On the other hand, the use of 100 mg sumatriptan and
550 mg naproxen sodium reduced recurrence from 59%
to 25,5% (p < 0.0003) compared to the use of
sumatriptan plus placebo [41]. Another 5-HT agonist, the
Rizatriptan, was also studied in combination with a mem-
ber of a new class of NSAID, known as COX-2 selective
inhibitors, characterized by better tolerability in regard to
gastrointestinal side effects. In this study we suggested that
a fast acting triptan such as Rizatriptan 10 mg combined
with a long plasma half-life COX-2 inhibitor such as
Rofecoxib 25 mg reduced recurrence, provided better sus-
tained pain-free rates and demonstrated a trend for better
efficacy rates with regard to headache and nausea relief
when compared to the single use of Rizatriptan [42].
Recently we have demonstrated that 10 mg Rizatriptan
plus 50 mg rofecoxib was more efficient than rizatriptan
alone and the combination of rizatriptan plus 200 mg
tolfenamic acid with regard to pain-free rates at 2 hours (p
= 0.008 and p = 0.007, respectively) and photophobia at
2- and 4-hour timepoints (p = 0.010 and p = 0.023, Riza-
triptan + Rofecoxib vs. Rizatriptan; p = 0.003 and p =
0.015, Rizatriptan + Rofecoxib vs. Rizatriptan +
Tolfenamic acid). Recurrence was also significantly
reduced with both combinations in comparison to riza-
triptan alone (50% vs. 15,4%, Rizatriptan vs. rizatriptan +
Rofecoxib; 50% vs. 7,7%, Rizatriptan vs. Rizatriptan +
Tolfenamic acid). In this study (submitted for publica-
tion), 33 patients treated 184 moderate or severe attacks
in a randomized counterbalanced order with rizatriptan
alone, rizatriptan plus rofecoxib and rizatriptan plus
tolfenamic acid. Side effects didn't differ significantly
between the attacks treated with the three options.
Summary
Although these evidences clearly suggest advantages with
the combination of drugs acting on different mechanisms
involved in migraine, there is still a lack of controlled
studies to support it. Despite that, drug combinations in
migraine treatment are common among specialists. Fortu-
nately, significant recent scientific progress has led to the
ability to develop rational polytherapeutic regimens in
migraine [14]. We propose that the subset of patients not
having achieved pain-free status in up to 2 hours or not
presenting sustained pain-free for 24 hours in at least 5
previous migraine attacks with their current acute treat-
ment options undergo combination therapy with simple
analgesics or NSAID plus a triptan or a gastro kinetic drug
such as 20 mg metoclopramide or 30 mg domperidone orBMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/4
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200 mg trimebutine. The simultaneous use of these three
classes of substances must be considered for those still
remaining unresponsive to the proposed treatment objec-
tives. In addition, changing the strategy of utilization for
the chosen drugs may also improve efficacy and outcome.
For those patients rapid developing severe headache, a
combination of 6 mg injectable sumatriptan plus 100 mg
rectal indometacin seems to be very effective. If nausea is
a critical issue for that specific patient the use rectal meto-
clopramide or the administration of oral domperidone at
the first sign of the attack may be useful as well. Patients
have to be clearly informed with regard to the drug usage
frequency limitations (up to two times a week, not nego-
tiable!) since it is not desirable that the potential gained
with the drug combination translates into a higher poten-
tial for drug overuse. As we break the current paradigm of
treating all patients with monotherapy and the clinical
experience expands in the future, the perspectives of iden-
tifying rapid, consistent and complete polytherapy for
migraineurs will develop and certainly solidify and allow
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